Sam is Head of Market Access Canada at Incyte Biosciences Canada and joins the podcast to discuss the evolving market access landscape in Canada. As part of his conversation with Louise, he describes the unique challenges that market access leaders in the country are facing.

Useful resources referenced in this podcast:

March 2024 - Canadian Health Policy Institute (Patented Medicines Expenditure in Canada 1990 – 2022)

https://www.canadianhealthpolicy.com/product/patented-medicines-expenditure-in-canada-1990-2022-8th-edition/

January 2024 – Conference Board of Canada (Patented Medicines Expenditure in Canada 1990–2022 8TH Edition)

https://www.conferenceboard.ca/wp-content/uploads/2022/10/access-and-time-to-patient_jan2024.pdf

Innovative Medicines Canada – Access to Medicine

https://innovativemedicines.ca/browse-by/access-to-medicine/

April 2023 – Canadian Health Policy Journal (New cancer drugs in Canada 2012 to 2021: an economic analysis of cost, benefit, availability, and public insurance coverage)

https://www.canadianhealthpolicy.com/wp-content/uploads/2022/01/SKINNER-APR-23-New-cancer-drugs-in-Canada-2012-to-2021-final-1.pdf

April 2022 – Canadian Health Policy Institute (Access to New Medicines in Canada 2016 – 2021)

https://www.canadianhealthpolicy.com/posts/access-to-new-medicines-in-canada-2016-2021-federal-provincial-public-drug-programs-and-private-sector-drug-plans/

The opinions shared in this podcast are Sam’s own views and not representative of the company he is working for.

In this episode we're joined by Joao Carrasco, Director, Global Market Access Team at Bayer Pharmaceuticals. With a 12+ year career spanning both HEOR and Market Access functions, Joao shares his journey and how his strong HEOR background informs his current role.

Joao also explores the key pressures and challenges market access teams are facing and his views on the trends shaping the future of market access.

The opinions shared in this episode are Joao's own views and not representative of the company he is working for.

In this episode we look at market access through a different lens. We're joined by Becky Germino who has extensive experience in HEOR across a broad range of pharma organisations.
Becky joined Sanofi this year as HEVA, Neurology and Immunology Team Leader and explains the key priorities for HEOR teams and their role in working closely with market access to help them define and communicate patient value.
The discussion also explores the role of AI for HEOR and market access teams and what's on the horizon that leaders should prepare for.

The opinions shared in this episode are Becky's own views.

Adrian Harrington, Senior Director Value and Access at Biogen, joins the podcast to discuss market access excellence – what it means to him, and the critical role visual communication is playing for market access leaders.

Adrian also shares his views on what’s next for the market access function, detailing why leaders must embrace opportunities to demonstrate the value of market access and tell the story of their team’s success.

Strong communication strategies are clearly important to Adrian and it’s a theme that sits at the heart of this episode.

The opinions shared in this episode are Adrian's own views and not representative of the company he is working for.

In this special episode, Louise teams up with colleagues Thomas Gilboy and Shravani Madishetti from Access Infinity to explore the transformative impact of digital on market access. Shravani, APAC Pricing and Market Access Lead, highlights the efficiency and accuracy achieved through digital tools while Tom, Product Owner for Nuro, emphasises the importance of maximising the effectiveness of digital tools. Together, they offer valuable insights and practical guidance for navigating this evolving landscape.

In the third episode of series 2, Louise interviews Khalid Mirza, Senior Director, Global Market Access & Pricing, Oncology at Daiichi Sankyo.
They discuss Khalid's journey into market access, and how, for him, it's evolved into an exciting career path where science meets commercial.
They also touch on the key themes shaping the future of market access, where Khalid's positive energy and passion for the function shines.

The opinions shared in this episode are Khalid's own views and not representative of the company he is working for.

In this episode Louise teams up with Access Infinity Partner, Nick Proctor. Nick has been a consultant in the biopharmaceutical industry for over twenty years and shares his views on the hot topics and trends which he feels will have the biggest impact on market access in the coming years, also offering his insights on the themes which are 'hype'.
Throughout his career Nick has also been responsible for training, coaching and mentoring others in global market access and pricing, and talks to Louise about his passion for empowering aspiring market access leaders on their own professional growth journeys.

Welcome back to the Market Access Matters podcast! In the first episode of series 2, Louise interviews David McConkey, Virology and Oncology Global Value and Access Director at Gilead Services.
Having started his career in consulting and then working across global and country roles, David has a breadth of experience in market access.
In this discussion he shares his experiences of taking on new challenges, leading teams into new territories and what he's learnt along the way.

The opinions shared in this episode are David's own views and not those of the company he is working for.